Alnylam Pharmaceuticals 株価情報 (NASDAQ: ALNY)

最新ニュース Alnylam Pharmaceuticals (NASDAQ:ALNY) 株価情報

ALNYLAM PHARMACEUTICALS INC

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Large Cap

News

Movers

ALNY

CVNA

FTAI

MSTR

RDDT

RIVN

過去1週間でこれらの10本の大型株は最も良いパフォーマンスを発揮しました。投資ポートフォリオには含まれていますか？Rivian Automotive, Inc. (NASDAQ:RIVN)の株は、同社が生産を単純化し、コストを削減し、フォルクスワーゲンとの 合弁事業を発表したという報告書に続き、先週30.04％急騰しました。

過去1週間の大型株を特集　米国市場での存在感は

Equities

Markets

AFRM

NVDA

TSLA

月曜日、米国の主要株価指数は反発しました。ダウ平均株価は0.7％以上の上昇で39,411.21ドルで終了し、一方でS&amp;P500は0.3％減の5,447.87ドルでした。ナスダックは約1.1％減の17,496.82でした。

Nvidiaが米国の主要株価指数を牽引　

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.09% on an annualized basis producing an average annual return of 20.51%. Currently, Alnylam Pharmaceuticals has a market capitalization of $39.93 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $40,864.67 today based on a price of $308.54 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750089617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years

Ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00. Surpassing the previous average price target of $324.29, the current average has increased by 4.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1749736915_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Alnylam Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$338.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Esther Rajavelu</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$349.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$342.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Joshua Smith</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$353.00</td>
<td>-</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$328.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$351.00</td>
<td>$338.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$338.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$287.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Alnylam Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Alnylam Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Alnylam Pharmaceuticals's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 20.2%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Alnylam Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -9.67%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -62.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 11.28, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $330 to $338.

Price Target

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $338

The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis in adults.

Biotech

Health Care

General

The European Commission Approves  Alnylam Pharmaceuticals' Orphan RNAi Therapeutic Amvuttra (Vutrisiran) For Wild-type Or Hereditary Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy As An Additional Indication

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court&#8217;s finding of noninfringement in favor of Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) in its ongoing patent battle with Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) over mRNA-based <a href="https://www.benzinga.com/topic/covid-19">COVID-19 vaccine technology</a>, including its Spikevax COVID-19 vaccine.
The court held that Alnylam had acted as its lexicographer in defining the term &#8220;branched alkyl&#8221; in its patent specifications. That definition was included in Alnylam&#8217;s infringement allegations against Moderna&#8217;s Spikevax vaccine.
The <a target="_blank" href="https://www.cafc.uscourts.gov/opinions-orders/23-2357.OPINION.6-4-2025_2525006.pdf" rel="noreferrer noopener">case</a> centered on whether Alnylam&#8217;s patents, U.S. Patent Nos.&nbsp;11,246,933&nbsp;and&nbsp;11,382,979 were infringed by Moderna&#8217;s use of SM-102-a cationic lipid in Moderna&#8217;s COVID-19 vaccine formulations.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
Alnylam asserted that SM-102 fell within the scope of its claims, specifically limitations requiring a &#8220;branched alkyl&#8221; group in the hydrophobic tail of a cationic lipid. SM-102 enables intracellular delivery of mRNA in Moderna&#8217;s vaccine, making it central to Alnylam&#8217;s infringement theory.
In March 2022, Alnylam sued Moderna, alleging that Moderna infringed claim 18 and other claims of the '933 patent through activities involving the SM-102 lipid in its mRNA-based COVID-19 vaccine.
In July 2022, after the '979 patent was issued, Alnylam filed a similar suit against Moderna in the same forum, alleging infringement of claim 1 and other claims of the '979 patent. The two <a target="_blank" href="https://www.benzinga.com/general/biotech/22/07/28082091/alnylam-hits-moderna-with-another-patent-infringement-suit-related-to-covid-19-vaccine" rel="noreferrer noopener">actions were consolidated</a>.
In October 2024, Alnylam and&nbsp;Moderna reached a stipulation in their ongoing&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41169029/alnylams-concedes-its-patent-infringement-case-against-modernas-covid-19-vaccine" rel="noreferrer noopener">patent infringement litigation</a>.
Based on the court&#8217;s claim construction, Alnylam acknowledged it couldn&#8217;t secure a favorable judgment regarding the accused products&#8217; infringement of its patents.
The final stipulation allows for judgment in favor of Moderna, confirming that its currently formulated products do not infringe on Alnylam&#8217;s patents.
Both parties have agreed to dismiss the counterclaims and affirmative defenses raised by Moderna without prejudice, leaving the door open for further legal action if necessary in the future.
In October 2024, Northwestern University filed a patent infringement lawsuit against&nbsp;Moderna, alleging the pharmaceutical company used the university&#8217;s lipid nanoparticle (LNP) technology without permission to develop&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology" rel="noreferrer noopener">its COVID-19 vaccines.</a>
According to the&nbsp;<a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/dwpkkdaxjpm/NORTHWESTERN%20MODERNA%20PATENT%20LAWSUIT%20complaint.pdf?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">lawsuit</a>, the development of Moderna&#8217;s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern.
Recently, The U.S. Food and Drug Administration (FDA) approved Moderna&#8217;s mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factors as defined by the Centers for Disease&nbsp;<a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
Moderna shared Phase 3 immunogenicity data for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 and older at its 2024 R&amp;D Day event.&nbsp;
The company submitted mRNA-1083 for regulatory approval in older adults in 2024. Based on FDA feedback confirming the need for Phase 3 flu efficacy data, Moderna expects an extended review timeline and is now <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45145598/moderna-expands-cost-cutting-program-by-up-to-17-billion-fda-approval-for-flucovid-19-combo-shot-delayed-into-2026" rel="noreferrer noopener">targeting approval in 2026</a>.
Price Action: MRNA stock is down 1.32% at $26.91, and ALNY stock is up 0.69% at $307.43 at last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45790736/ciena-stock-slides-after-q2-eps-miss-margin-drop-despite-strong-sales" target="_blank" rel="noreferrer noopener">Ciena Stock Slides After Q2 EPS Miss, Margin Drop Despite Strong Sales</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Legal

MRNA

Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 12.14% on an annualized basis producing an average annual return of 20.3%. Currently, Alnylam Pharmaceuticals has a market capitalization of $36.66 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on a price of $283.25 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748302212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin –
– Additional 42-Month Data Reinforce Vutrisiran's Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality –
– Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular Events, Notably Reducing Urgent Heart Failure Visits by 46% in the Overall Patient Population During the Double-Blind Period –
– Findings Simultaneously Published in JACC –
– Details of TRITON-CM Phase 3 Study Evaluating Alnylam's Investigational Next-Generation TTR Silencer, Nucresiran, to be Presented at Congress –

Reported Saturday, Alnylam's Vutrisiran Reduces All-Cause And Cardiovascular Mortality By Over 30% In ATTR-CM Patients, New 42-Month HELIOS-B Data Show

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54252800&amp;newsitemid=20250512731729&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=c09d64a6df2c8aec7de70fcaf5351a15">Alnylam Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia.
The latest analyses of the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract in the "Hottest Trials and Trial Updates 1" session.
Data from the HELIOS-B study supported the recent approvals of AMVUTTRA&#xAE; (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of vutrisiran for the same indication. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year.
Additional updates to be presented include the design and rationale of the TRITON-CM Phase 3 study of nucresiran (ALN-TTRsc04), an investigational next-generation TTR silencer, in patients with ATTR-CM, as well as an additional analysis from the HELIOS-B study of vutrisiran in patients with ATTR-CM who experienced disease progression while being treated with tafamidis.

Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.44 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,535.06 today based on a price of $258.35 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746743413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

UBS analyst Esther Rajavelu maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $331 to $349.

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $349

Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of $(1.03)</a>.
The company reported quarterly sales of $594.2 million, up 20% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45132168/alnylam-pharmaceuticals-reports-first-quarter-2025-financial-results-and-highlights-recent-period-" rel="noreferrer noopener">consensus of $585.8 million</a>.
<ul>
<li>Net product revenues increased 28% and 30% at actual currency and CER, respectively, due to growth from Amvuttra driven by increased patient demand, partially offset by a decrease in Onpattro due to patient switches to Amvuttra, and an increased number patients on Givlaari.</li>
<li><a href="https://www.benzinga.com/25/03/44463008/jp-morgan-sees-convincing-multi-billion-dollar-opportunity-for-alnylam-pharmaceuticals-upgrades-stock" target="_blank" rel="noreferrer noopener">Amvuttra</a> and Onpattro sales for the first quarter reached&nbsp;$310 million&nbsp;and&nbsp;$49 million, respectively, representing 36% growth compared to Q1 2024.</li>
<li>Givlaari and Oxlumo sales reached $67 million&nbsp;and&nbsp;$42 million, respectively, representing 8% growth.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks" rel="noreferrer noopener">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a>
Guidance: Alnylam affirmed fiscal 2025 sales guidance of $2.70 billion-$3 billion compared to the consensus of $2.91 billion, including:
<ul>
<li>Total TTR net product revenues (Amvuttra and Onpattro) of $1.6 billion-$1.725 billion.</li>
<li>Total rare net product revenues (Givlaari and Oxlumo) of $450 million&nbsp;&#8211;&nbsp;$525 million.</li>
</ul>
On Monday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Alnylam&#8217;s vutrisiran for wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). European Commission decision is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45036384/alnylam-receives-positive-chmp-opinion-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-c" rel="noreferrer noopener">expected in June 2025</a>.
&#8220;Commercially, we believe that the totality of the data leaves Amvuttra well positioned to achieve significant market share as 1st line therapy, and we are encouraged by the launch activities discussed on the conference call,&#8221; Chardan analyst Keay Nakae writes.
Nakae maintains the Buy rating with a<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings" target="_blank" rel="noreferrer noopener"> price target of $325</a>.
William Blair analyst Myles R. Minter writes, &#8220;On the ongoing Section 232 review of potential pharmaceutical tariffs, management highlighted minimal predicted exposure given that the majority of manufacturing processes and IP are housed within the U.S.&#8221;
Minter writes, &#8220;We continue to see Amvuttra as well positioned and differentiated in the lucrative TTR-CM market and would be buyers of Alnylam stock ahead of future quarters. Despite intraday volatility in trading, in part due to investor questions over why TTR-CM launch metrics like patient or script volume numbers were not provided when they are for BridgeBio Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) Attruby, we believe management remains confident about Amvuttra&#8217;s potential and early access/reimbursement metrics provided appear favorable for a product in the infancy of a launch.&#8221;
Price Action: ALNY stock was up 1.67% at $259.39 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/05/45169853/taiwan-semiconductor-gains-on-strong-earnings-from-meta-and-microsoft-boosting-ai-demand" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Gains On Strong Earnings From Meta And Microsoft Boosting AI Demand</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Analyst Color

Earnings

Guidance

BBIO

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group cut Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) price target from $10 to $9. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Kohl&#8217;s shares closed at $7.21 on Thursday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from $400 to $460. Needham analyst Ryan MacDonald maintained a Buy rating. Duolingo shares closed at $400.00 on Thursday. <a href="https://www.benzinga.com/quote/DUOL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital raised Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $300 to $325. Chardan Capital analyst Keay Nakae maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $255.13 on Thursday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity slashed the price target for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from $100 to $80. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Block shares closed at $58.48 on Thursday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>D. Boral Capital cut the price target for GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) from $14 to $9. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. GeoVax Labs shares closed at $0.9893 on Thursday. <a href="https://www.benzinga.com/quote/GOVX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $230 to $250. DA Davidson analyst Gil Luria maintained a Buy rating. Apple shares settled at $213.32 on Thursday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) price target from $52 to $10. Jefferies analyst Akash Tewari downgraded the stock from Buy to Hold. Arvinas shares closed at $7.23 on Thursday. <a href="https://www.benzinga.com/quote/ARVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) price target from $42 to $32. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Clear Secure shares closed at $24.40 on Thursday.  <a href="https://www.benzinga.com/quote/YOU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham lowered the price target for Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) from $52 to $40. Needham analyst Scott Berg maintained a Buy rating. Five9 shares settled at $25.08 on Thursday. <a href="https://www.benzinga.com/quote/FIVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Strategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) price target from $409 to $464. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Strategy shares closed at $381.60 on Thursday. <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png" alt="" class="wp-image-898959" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-768x454.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AAPL

ARVN

DUOL

FIVN

GOVX

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $300 to $325.

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 11.06% on an annualized basis producing an average annual return of 19.26%. Currently, Alnylam Pharmaceuticals has a market capitalization of $34.08 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a price of $263.34 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746112529_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals Affirms FY2025 Sales Guidance of $2.70B-$3.00B vs $2.91B Est

Earnings Beats

Alnylam Pharmaceuticals Q1 Adj. EPS $(0.01) Beats $(1.03) Estimate, Sales $594.19M Beat $585.82M Estimate

AAMI

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

Alnylam Receives Positive CHMP Opinion For Vutrisiran In Treatment Of ATTR Amyloidosis With Cardiomyopathy

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has risen 17.69% since its last report. The company recently reported that it has 2.99 million shares sold short, which is 3.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745254820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 8.52% on an annualized basis producing an average annual return of 19.0%. Currently, Alnylam Pharmaceuticals has a market capitalization of $29.89 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,352.84 today based on a price of $230.93 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744758911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years

Press Releases

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

Alnylam Issues 2024 Corporate Responsibility Report

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Management

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

AbbVie

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

JP Morgan

Chardan Capital

Morgan Stanley

Needham

過去1週間でこれらの10本の大型株は最も良いパフォーマンスを発揮しました。投資ポートフォリオには含まれていますか？
<ol>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)の株は、同社が生産を単純化し、コストを削減し、フォルクスワーゲンとの <a href="https://www.benzinga.com//node/39497161" target="_blank" rel="noreferrer noopener">合弁事業を発表した</a>という報告書に続き、先週30.04％急騰しました。</li>
<li>Carnival Plc（NYSE:CUK）の株は、<a href="https://www.benzinga.com//node/39481992" target="_blank" rel="noreferrer noopener">予想を上回る第2四半期の決算</a>を受けた株価の持続的な強さにより17.78％上昇しました。</li>
<li>FedEx Corporation（NYSE:FDX）の株は先週、予想を上回る第4四半期の財務諸表と業績予測により17.51％急騰しました。さらに、同社は「2025年度に株式2.5十億ドルを自社株買いのために買い戻す見通し」としている<a href="https://www.benzinga.com//node/39504381" target="_blank" rel="noreferrer noopener">（リンク先PDF）</a>と発表しました。複数のアナリストが株価予測を引き上げました。<a href="https://www.benzinga.com//node/39509568" target="_blank" rel="noreferrer noopener">（リンク先PDF）</a></li>
<li>多くのアナリストが「強気」のレーティングを維持し、<a href="https://www.benzinga.com/quote/iot/analyst-ratings" target="_blank" rel="noreferrer noopener">価格ターゲットを47ドルに維持し</a>たことを受け、RBCキャピタルがアウトパフォーム評価を再確認したことから、Samsara Inc. （NYSE:IOT）の株価は16.37％上昇しました。</li>
<li>Suzano S.A.（NYSE:SUZ）の株は、同社がInternational Paper Co.（NYSE:IP）の買収を<a href="https://www.benzinga.com//node/39519611" target="_blank" rel="noreferrer noopener">取りやめたと発表したこと</a>を受け、12.24％上昇しました。</li>
<li>Carvana Co.（NYSE:CVNA）の株は、6月初旬のWilliam Blair株44回目の年次グロース株式投資<a href="https://www.benzinga.com//node/39509401" target="_blank" rel="noreferrer noopener">カンファレンスで、自社の運営計画と資本構造を更新した後、11.93％上昇しました。</a></li>
<li>FTAI Aviation Ltd.（NASDAQ:FTAI）の株は先週11.55％上昇しました。</li>
<li>Reddit, Inc.（NYSE:RDDT）の株は、同社が<a href="https://www.benzinga.com//node/39494776" target="_blank" rel="noreferrer noopener">自動ウェブサイトスクレイピングをブロックする方針を発表したこと</a>を受け、11.08％急騰しました。</li>
<li>Mongodb Inc（NASDAQ:MDB）の株は、先週10.57％急騰しました。</li>
<li>Alnylam Pharmaceuticals, Inc.（NASDAQ:ALNY）の株は、同社がvutrisiranのHELIOS-B第3フェーズ試験のトップラインの結果を発表したことを受けて10.82％上昇しました。複数のアナリストが<a href="https://www.benzinga.com/quote/alny/analyst-ratings" target="_blank" rel="noreferrer noopener">同社の株価予測を引き上げた</a>と発表しました。</li>
</ol>

月曜日、米国の主要株価指数は反発しました。ダウ平均株価は0.7％以上の上昇で39,411.21ドルで終了し、一方でS&amp;P500は0.3％減の5,447.87ドルでした。ナスダックは約1.1％減の17,496.82でした。
以下は、この日一日中小売トレーダーや投資家の関心を集めたトップ銘柄です。
Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
Nvidiaの株は6.68％減の118.11ドルで取引を終えました。株の日中の高値は124.46ドル、安値は118.04ドルでした。株の52週レンジは39.23ドルから140.76ドルの間です。この半導体企業はCEOのJen Huangが1億ドル以上の株式を売却した<a href="https://www.benzinga.com/markets/equities/24/06/39462808/semiconductor-nvidia-woes-deepen-nasdaq-100-slips-dow-rallies-bitcoin-sinks-to-60-400-whats-driv">売り勢の後</a>に、株価は訂正進入しました。
Affirm Holdings Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)
Affirmの株は12.82％上昇し、33.70ドルで取引を終了しました。株の日中の高値は34.13ドル、安値は30.77ドルでした。株の52週レンジは12.81ドルから52.48ドルの間です。ゴールドマン・サックスのアナリストWill NanceがAffirmの株式をBuy評価と42ドルの目標株価でカバーしました。
Carnival Corporation(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>)
Carnivalの株は1.99％上昇し、16.39ドルで取引を終了しました。その日の株の最高値は16.5ドル、最安値は16ドルでした。この株の52週レンジは10.84ドルから19.74ドルの間です。同社は火曜日に<a href="https://www.benzinga.com/general/entertainment/24/06/39464753/carnival-stock-in-strong-bullish-trend-ahead-of-q2-earnings-why-analyst-sees-multiyear-port">四半期決算</a>を発表する予定で、ウォール街は純利益20セント/株、売上高57億ドルを予想しています。
Alnylam Pharmaceuticals, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>)
Alnylamの株は34.52％急騰し、222.90ドルで終了しました。株の日中の高値は231.64ドル、安値は209.23ドルでした。この株の52週レンジは141.98ドルから231.64ドルの間です。株価は同社が開発中のATTR心筋症向けのRNAi治療薬であるvutrisiranのHELIO-Bフェーズ3試験で<a href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s">良好な結果を発表した後</a>に上昇しました。
Tesla Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Teslaの株はわずか0.23％減の182.58ドルで取引を終了しました。株の日中の高値は188.8ドル、安値は182.55ドルでした。株の52週レンジは138.8ドルから299.29ドルの間です。Gary Blackが、Delaware州の裁判官が「Tornetta vs. Musk」事件で<a href="https://www.benzinga.com/news/24/06/39449373/tesla-bull-gary-black-slams-delaware-chancellors-judicial-activism-in-elon-musks-56b-pay-package-cas">司法活動を行ったと批判</a>しました。この事件は、TeslaのElon Muskが保有する560億ドルの報酬パッケージを争うものであり、司法の役割や立法の対応についての広範な議論を呼びました。
株価の予想動きとビジネスニュースのトップで、ベンジンガによる本日の取引に備えよ。
このストーリーは<a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>によって生成されたもので、<a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>によって編集されました。

Comments

Alnylam Pharmaceuticals

ニュース

最新ニュース Alnylam Pharmaceuticals (NASDAQ:ALNY) 株価情報

月曜日, 7 01, 2024

火曜日, 6 25, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル